6-K: Dupixent Approved in the EU as the First-Ever Targeted Therapy for Patients with COPD and NEJM Publishes ALTUVIIIO XTEND-Kids Phase 3 Data Supporting Its Potential to Transform the Treatment Landscape for Children with Severe Hemophilia A
6-K: Dupixent Approved in the EU as the First-Ever Targeted Therapy for Patients with COPD and NEJM Publishes ALTUVIIIO XTEND-Kids Phase 3 Data Supporting Its Potential to Transform the Treatment Landscape for Children with Severe Hemophilia A
6-K：Dupixent在欧盟获批成为首个针对COPD患者的靶向治疗药物以及NEJM发布ALTUVIIIO XTEND-Kids第3阶段数据，支持其改变重症A型血友病儿童治疗前景的潜力